시장보고서
상품코드
1964350

자가 증폭 RNA 합성 시장 규모, 점유율, 성장 분석 : 제품 유형별, 기술별, 응용 분야별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Self-amplifying RNA Synthesis Market Size, Share, and Growth Analysis, By Product Type (Premade saRNA, Enzymes & Reagents), By Technology, By Application Area, By Route of Administration, By End User, By Region - Industry Forecast 2026-2033

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 157 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 자가 증폭 RNA 합성 시장 규모는 2024년에 1억 643만 달러로 평가되었으며, 2025년 1억 2,686만 달러에서 2033년까지 5억 1,707만 달러로 성장할 전망입니다. 예측 기간(2026-2033년) 동안 CAGR은 19.2%로 예측됩니다.

세계 자가 증폭 RNA 합성 시장은 RNA 분자가 세포 내에서 복제할 수 있는 혁신적인 생산 기술에 초점을 맞추고 있으며, 백신 및 치료제의 용량 요건과 비용을 크게 절감할 수 있습니다. 이러한 변화로 인해 건강 응급 상황에서의 접근성 향상과 신속한 대응이 가능해져 생명공학 기업 및 수탁 제조업체의 관심이 높아지고 있습니다. 시장의 발전은 in vitro 전사, 나노입자 전달, 규제에 대한 이해의 진전에 힘입어 초기 학술 연구에서 초기 임상시험으로 발전해 왔습니다. 제조의 확장성은 매우 중요합니다. 자가증폭을 통해 필요한 RNA의 양을 줄일 수 있기 때문에 소규모 생산 로트에서도 광범위한 수요에 대응할 수 있습니다. AI 기술은 설계 및 제조 공정의 자동화, 배열 최적화, 결과 예측, 매개변수 정교화를 통해 효율성을 향상시키고 개발 기간 단축 및 폐기물 최소화를 실현합니다. 이는 생산능력과 시장 기회의 성장을 촉진할 수 있습니다.

세계 자가 증폭 RNA 합성 시장의 촉진요인

최근 지질 나노입자 제제, 표적 전달 리간드, 제조 기술의 발전으로 자가증폭형 RNA 구축체의 안정성, 세포 내 흡수성, 조직 표적성이 크게 향상되었습니다. 이러한 혁신을 통해 복용량을 최소화하면서 보다 효과적인 번역과 치료 효과를 얻을 수 있습니다. 생물학적 장벽을 낮추는 이러한 전달 기술의 개선은 전신 및 국소 투여의 실용성을 높이고, 산업계와 학계 연구자 간의 투자와 협력을 촉진할 것입니다. 결과적으로, 이러한 협업 환경은 개발 파이프라인에서 신제품 후보물질의 진전을 가속화하고, 시장 신뢰도를 높이며, 치료 개발자들 사이에서 자가 증폭 RNA 합성 솔루션의 광범위한 채택을 촉진할 수 있습니다.

세계 자가 증폭 RNA 합성 시장의 억제요인

자가증폭형 RNA의 합성은 정교한 제조, 정제, 제제화 과정을 포함한 복잡한 워크플로우가 특징입니다. 이러한 요구사항은 고도의 기술적 전문 지식과 특수한 시설을 필요로 하며, 시장 진입을 원하는 중소규모의 기업에게는 도전이 될 수 있습니다. 제조의 복잡성은 개발 기간의 연장 및 생산량 제한을 초래하고, 공급망 병목현상 발생 가능성으로 이어집니다. 또한, 맞춤형 프로세스 검증의 필요성과 숙련된 인력 확보는 운영상의 장벽과 고정비 증가 요인으로 작용합니다. 결과적으로 이러한 요인들은 새로운 후보물질의 신속한 생산을 방해하고 시장의 전반적인 성장을 저해하는 요인이 될 수 있습니다.

세계 자가 증폭 RNA 합성 시장 동향

세계 자가 증폭 RNA 합성 시장은 전달 플랫폼의 혁신에 힘입어 혁신적 전환기를 맞이하고 있습니다. 개발자들이 자가증폭형 RNA 치료제의 안정성, 세포 내 흡수, 표적 발현을 개선하는 가운데, 조직 특이성 및 투여 편의성을 개선하기 위해 첨단 지질 제제, 벡터 설계, 결합 방식에 대한 명확한 초점이 맞춰지고 있습니다. 이러한 돌파구를 통해 시장의 치료 대상 범위는 백신을 넘어 지속적인 발현과 저빈도 투여를 통해 만성질환 및 희귀질환에 대한 적용이 가능해졌습니다. 또한, 전략적 투자와 연구 협력은 플랫폼의 성숙을 촉진하고 있으며, 전달 성능과 환자 중심의 투여 옵션을 중심으로 경쟁 우위를 제공하는 명확한 제품 프로파일을 창출하고 있습니다.

자주 묻는 질문

  • 세계 자가 증폭 RNA 합성 시장 규모는 어떻게 변할 것으로 예상되나요?
  • 자가 증폭 RNA 합성 시장의 주요 촉진 요인은 무엇인가요?
  • 자가 증폭 RNA 합성 시장의 억제 요인은 무엇인가요?
  • 세계 자가 증폭 RNA 합성 시장의 동향은 어떤가요?
  • 자가 증폭 RNA 합성 시장에서 AI 기술의 역할은 무엇인가요?

목차

소개

조사 방법

주요 요약

시장 역학과 전망

주요 시장 인사이트

세계의 자가 증폭 RNA 합성 시장 규모 : 제품 유형별 & CAGR(2026-2033년)

세계의 자가 증폭 RNA 합성 시장 규모 : 기술별 & CAGR(2026-2033년)

세계의 자가 증폭 RNA 합성 시장 규모 : 응용 분야별 & CAGR(2026-2033년)

세계의 자가 증폭 RNA 합성 시장 규모 : 투여 경로별 & CAGR(2026-2033년)

세계의 자가 증폭 RNA 합성 시장 규모 : 최종사용자별 & CAGR(2026-2033년)

세계의 자가 증폭 RNA 합성 시장 규모 & CAGR(2026-2033년)

경쟁 정보

주요 기업 개요

결론과 제안

KSM 26.03.23

Global Self-Amplifying Rna Synthesis Market size was valued at USD 106.43 Million in 2024 and is poised to grow from USD 126.86 Million in 2025 to USD 517.07 Million by 2033, growing at a CAGR of 19.2% during the forecast period (2026-2033).

The global self-amplifying RNA synthesis market focuses on innovative production technologies allowing RNA molecules to replicate within cells, significantly lowering vaccine and therapeutic dosage requirements and costs. This shift facilitates greater accessibility and quicker responses during health emergencies, drawing increased interest from biotech companies and contract manufacturers. Market development has evolved from early academic investigations to initial clinical trials, boosted by advancements in in vitro transcription, nanoparticle delivery, and regulatory familiarity. Manufacturing scalability is crucial, as self-amplification reduces the necessary RNA mass, enabling smaller production runs while meeting extensive demands. AI technology enhances efficiency by automating design and manufacturing processes, optimizing sequences, predicting outcomes, and refining parameters, thereby shortening development timelines and minimizing waste, thus propelling growth in both production capabilities and market opportunities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Self-Amplifying Rna Synthesis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Self-Amplifying Rna Synthesis Market Segments Analysis

Global self-amplifying rna synthesis market is segmented by product type, technology, application area, route of administration, end user and region. Based on product type, the market is segmented into Premade saRNA, Enzymes & Reagents, Kits & Consumables and Other Related Products. Based on technology, the market is segmented into In Vitro Synthesis and In Vivo Synthesis. Based on application area, the market is segmented into Therapeutics Development and Biomedical Research. Based on route of administration, the market is segmented into Intramuscular (IM), Subcutaneous (SC), Intradermal (ID) and Intravenous (IV). Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Development & Manufacturing Organizations (CDMOs), Academic & Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Self-Amplifying Rna Synthesis Market

Recent advancements in lipid nanoparticle formulations, targeted delivery ligands, and manufacturing techniques have significantly enhanced the stability, cellular absorption, and tissue targeting of self-amplifying RNA constructs. These innovations lead to more effective translation and therapeutic effects while minimizing dosage requirements. By mitigating biological barriers, these delivery enhancements improve the viability of both systemic and localized applications, fostering increased investment and collaboration between industry and academic researchers. Consequently, this collaborative environment accelerates the progression of new product candidates through the development pipeline, bolstering market confidence and promoting wider adoption of self-amplifying RNA synthesis solutions among therapeutic developers.

Restraints in the Global Self-Amplifying Rna Synthesis Market

The synthesis of self-amplifying RNA is characterized by complex workflows that involve meticulous production, purification, and formulation processes. These requirements demand significant technical expertise and specialized facilities, which can create challenges for smaller companies aiming to enter the market. The intricate nature of manufacturing can extend development timelines and restrict throughput, leading to potential supply chain bottlenecks. Additionally, the necessity for customized process validation and the recruitment of skilled personnel contribute to higher operational barriers and fixed costs. Consequently, these factors hinder the rapid production of new candidates, ultimately restraining the overall growth of the market.

Market Trends of the Global Self-Amplifying Rna Synthesis Market

The Global Self-Amplifying RNA Synthesis market is experiencing a transformative shift driven by innovations in delivery platforms. As developers enhance stability, cellular uptake, and targeted expression of self-amplifying RNA therapeutics, there is a clear focus on advanced lipid formulations, vector engineering, and conjugation methods to improve tissue specificity and dosing convenience. These breakthroughs expand the market's therapeutic reach beyond vaccines, facilitating applications in chronic and rare diseases through sustained expression with lower administration frequency. Furthermore, strategic investments and research collaborations are fostering platform maturation, resulting in distinct product profiles that offer competitive advantages centered on delivery performance and patient-centric administration options.

Table of Contents

Introduction

  • Objectives of the Study
  • Market Definition & Scope

Research Methodology

  • Research Process
  • Secondary & Primary Data Methods
  • Market Size Estimation Methods

Executive Summary

  • Global Market Outlook
  • Key Market Highlights
  • Segmental Overview
  • Competition Overview

Market Dynamics & Outlook

  • Macro-Economic Indicators
  • Drivers & Opportunities
  • Restraints & Challenges
  • Supply Side Trends
  • Demand Side Trends
  • Porters Analysis & Impact
    • Competitive Rivalry
    • Threat of Substitute
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factors
  • Market Impacting Factors
  • Top Investment Pockets
  • Ecosystem Mapping
  • Market Attractiveness Index 2025
  • PESTEL Analysis
  • Regulatory Landscape
  • Technology Analysis
  • Value Chain Analysis

Global Self-amplifying RNA Synthesis Market Size by Product Type & CAGR (2026-2033)

  • Market Overview
  • Premade saRNA
  • Enzymes & Reagents
  • Kits & Consumables
  • Other Related Products

Global Self-amplifying RNA Synthesis Market Size by Technology & CAGR (2026-2033)

  • Market Overview
  • In Vitro Synthesis
  • In Vivo Synthesis

Global Self-amplifying RNA Synthesis Market Size by Application Area & CAGR (2026-2033)

  • Market Overview
  • Therapeutics Development
    • Infectious Diseases
    • Oncology
    • Gene & Protein Therapy
    • Other Therapeutic Applications
  • Biomedical Research

Global Self-amplifying RNA Synthesis Market Size by Route of Administration & CAGR (2026-2033)

  • Market Overview
  • Intramuscular (IM)
  • Subcutaneous (SC)
  • Intradermal (ID)
  • Intravenous (IV)

Global Self-amplifying RNA Synthesis Market Size by End User & CAGR (2026-2033)

  • Market Overview
  • Pharmaceutical & Biotechnology Companies
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Academic & Research Institutes
  • Others

Global Self-amplifying RNA Synthesis Market Size & CAGR (2026-2033)

  • North America (Product Type, Technology, Application Area, Route of Administration, End User)
    • US
    • Canada
  • Europe (Product Type, Technology, Application Area, Route of Administration, End User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Product Type, Technology, Application Area, Route of Administration, End User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Product Type, Technology, Application Area, Route of Administration, End User)
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Product Type, Technology, Application Area, Route of Administration, End User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Moderna, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BioNTech SE
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CureVac AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ginkgo Bioworks, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Zymeworks Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Imperial College London (Department of Chemical Engineering)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aarhus University
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GreenLight Biosciences, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Transgene SA
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • eTheRNA Immunotherapies
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Medigen Vaccine Biologics Corp.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vaxart, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Synlogic, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Tiba Biotech
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aibio Pharma
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Acuitas Therapeutics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • RiboBio Co., Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Codiak BioSciences, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • iBio, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Egenesis, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제